Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

Salvage therapy of multiple myeloma: the new generation drugs.

Romano A, Conticello C, Cavalli M, Vetro C, Di Raimondo C, Di Martina V, Schinocca E, La Fauci A, Parrinello NL, Chiarenza A, Di Raimondo F.

Biomed Res Int. 2014;2014:456037. doi: 10.1155/2014/456037. Epub 2014 May 19.

PMID:
24967371
[PubMed - in process]
Free PMC Article
2.

New drugs in multiple myeloma - role of carfilzomib and pomalidomide.

Jurczyszyn A, Legieć W, Helbig G, Hus M, Kyrcz-Krzemień S, Skotnicki AB.

Contemp Oncol (Pozn). 2014;18(1):17-21. doi: 10.5114/wo.2014.40175. Epub 2014 Jan 25. Review.

PMID:
24876816
[PubMed]
Free PMC Article
3.

Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib.

Harvey RD.

Clin Pharmacol. 2014 May 8;6:87-96. doi: 10.2147/CPAA.S62512. eCollection 2014. Review.

PMID:
24855395
[PubMed]
Free PMC Article
4.

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models.

Crawford LJ, Chan ET, Aujay M, Holyoake TL, Melo JV, Jorgensen HG, Suresh S, Walker B, Irvine AE.

Oncogenesis. 2014 Mar 3;3:e90. doi: 10.1038/oncsis.2014.3.

PMID:
24590311
[PubMed]
Free PMC Article
5.

Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.

Hu B, Chen Y, Usmani SZ, Ye S, Qiang W, Papanikolaou X, Heuck CJ, Yaccoby S, Williams BO, Van Rhee F, Barlogie B, Epstein J, Qiang YW.

PLoS One. 2013 Sep 16;8(9):e74191. doi: 10.1371/journal.pone.0074191. eCollection 2013.

PMID:
24066119
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R.

Blood. 2013 Oct 31;122(18):3122-8. doi: 10.1182/blood-2013-07-511170. Epub 2013 Sep 6.

PMID:
24014245
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.

Papadopoulos KP, Burris HA 3rd, Gordon M, Lee P, Sausville EA, Rosen PJ, Patnaik A, Cutler RE Jr, Wang Z, Lee S, Jones SF, Infante JR.

Cancer Chemother Pharmacol. 2013 Oct;72(4):861-8. doi: 10.1007/s00280-013-2267-x. Epub 2013 Aug 25.

PMID:
23975329
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S.

Haematologica. 2013 Nov;98(11):1753-61. doi: 10.3324/haematol.2013.089334. Epub 2013 Aug 9.

PMID:
23935022
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Association of response endpoints with survival outcomes in multiple myeloma.

Lonial S, Anderson KC.

Leukemia. 2014 Feb;28(2):258-68. doi: 10.1038/leu.2013.220. Epub 2013 Jul 19. Review.

PMID:
23868105
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.

Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S.

Leukemia. 2013 Dec;27(12):2351-6. doi: 10.1038/leu.2013.152. Epub 2013 May 14.

PMID:
23670297
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Flipping the switch from g1 to s phase with e3 ubiquitin ligases.

Rizzardi LF, Cook JG.

Genes Cancer. 2012 Nov;3(11-12):634-48. doi: 10.1177/1947601912473307.

PMID:
23634252
[PubMed]
Free PMC Article
12.

Novel agents in indolent lymphomas.

Merli M, Ferrario A, Basilico C, Maffioli M, Caramazza D, Appio L, Arcaini L, Passamonti F.

Ther Adv Hematol. 2013 Apr;4(2):133-48. doi: 10.1177/2040620712466865.

PMID:
23610620
[PubMed]
Free PMC Article
13.

From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes.

Kim KB, Crews CM.

Nat Prod Rep. 2013 May;30(5):600-4. doi: 10.1039/c3np20126k. Review.

PMID:
23575525
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

New strategies in the treatment of multiple myeloma.

Munshi NC, Anderson KC.

Clin Cancer Res. 2013 Jul 1;19(13):3337-44. doi: 10.1158/1078-0432.CCR-12-1881. Epub 2013 Mar 20. Review.

PMID:
23515406
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Multiple myeloma: an update.

Al-Farsi K.

Oman Med J. 2013 Jan;28(1):3-11. doi: 10.5001/omj.2013.02.

PMID:
23386937
[PubMed]
Free PMC Article
16.

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.

Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R.

Leukemia. 2013 Aug;27(8):1707-14. doi: 10.1038/leu.2013.29. Epub 2013 Jan 31.

PMID:
23364621
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma.

Fostier K, De Becker A, Schots R.

Onco Targets Ther. 2012;5:237-44. doi: 10.2147/OTT.S28911. Epub 2012 Sep 28.

PMID:
23055749
[PubMed]
Free PMC Article
18.
19.

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN.

Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5.

PMID:
22763387
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk